SARS-CoV-2 and hepatitis.

J Gastrointestin Liver Dis

Department of Medicine, Infectious Diseases Unit, Azienda Ospedale Università di Padova, Padova, Italy.

Published: September 2020

Download full-text PDF

Source
http://dx.doi.org/10.15403/jgld-2747DOI Listing

Publication Analysis

Top Keywords

sars-cov-2 hepatitis
4
sars-cov-2
1

Similar Publications

The emergence of RNA viruses driven by global population growth and international trade highlights the urgent need for effective antiviral agents that can inhibit viral replication. Nucleoside analogs, which mimic natural nucleotides, have shown promise in targeting RNA-dependent RNA polymerases (RdRps). Starting from protected 5-iodouridine, we report the synthesis of -substituted-(1,3-diyne)-uridines nucleosides and their phosphoramidate prodrugs.

View Article and Find Full Text PDF

Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice.

Viruses

November 2024

Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro 21040-361, RJ, Brazil.

Coronavirus disease 2019 (COVID-19) still causes death in elderly and immunocompromised individuals, for whom the sustainability of the vaccine response may be limited. Antiviral treatments, such as remdesivir or molnupiravir, have demonstrated limited clinical efficacy. Nirmatrelvir, an acute respiratory syndrome coronavirus 2 (SARS-CoV-2) major protease inhibitor, is clinically effective but has been associated with viral rebound and antiviral resistance.

View Article and Find Full Text PDF

The S1 subunit of SARS-CoV-2 Spike is crucial for ACE2 recognition and viral entry into human cells. It has been found in the blood of COVID-19 patients and vaccinated individuals. Using BioGRID, I identified 146 significant human proteins that interact with S1.

View Article and Find Full Text PDF

A Universal Strategy of Anti-Tumor mRNA Vaccine by Harnessing "Off-the-Shelf" Immunity.

Adv Sci (Weinh)

January 2025

National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, Zhejiang, 310058, China.

Personalized neoantigen cancer mRNA vaccines are promising candidates for precision medicine. However, the difficulty of identifying neoantigens heavily hinders their broad applicability. This study developed a universal strategy of anti-tumor mRNA vaccine by harnessing "off-the-shelf" immunity to known antigens.

View Article and Find Full Text PDF
Article Synopsis
  • CI-qPCR assays provide a viable alternative to traditional cell culture methods for assessing virus viability in wastewater, specifically focusing on human pathogens.
  • The study evaluated three CI-qPCR methods (Crosslinker, TruTiter, and PMAxx) on various viruses like HAdV and SARS-CoV-2, revealing differences in sensitivity and effectiveness between them.
  • Findings suggest that while PMAxx struggled with detecting certain heat-inactivated viruses, both PMAxx and TruTiter successfully identified intact viruses in wastewater, showing promise for improving public health monitoring and response to emerging viral threats.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!